NEW YORK (GenomeWeb) – Caris Life Sciences and North Shore Hematology Oncology Associates today announced they will create a personalized cancer care program leveraging Caris' tumor profiling service for patients in the Long Island, New York area.
The collaboration will use the Caris Molecular Intelligence service and includes clinical support and patient and physician education, the partners said, adding it also could include a research relationship.
Caris Molecular Intelligence correlates molecular data from a tumor with information about which therapies may be most beneficial and which may not be as useful for the patient. It also outlines clinical trials that may be suitable for the patient.
The service is based on next-generation sequencing methods, as well as traditional pathology analysis methods, such as immunohistochemistry and fluorescent in situ hybridization, the partners said.
Financial and other terms of the agreement were not disclosed.